US AI native pharmaceutical company Formation Bio today announced the Formation Bio Drug Development Accelerator Fund, with ...
Biopharma research and development has traditionally followed a familiar model. Scientists identified a target, generated ...
The Association of the British Industry (ABPI) has welcomed a Budget measure that removes a value added tax (VAT) charge on ...
German biotech BioNTech and its Chinese partner DualityBio have reported that the Phase III DYNASTY-Breast02 trial of ...
Swiss generic and biosimilars drugmaker Sandoz today presented its net-sales performance for the third quarter and first nine ...
Brinsupri (brensocatib hydrate) reached Japan during the 10 days to October 28, while China recorded the first prescription ...
Norwegian clinical-stage radiopharma company Oncoinvent, which is developing Radspherin, a receptor-independent ...
Swedish biotech AlzeCure Pharma (FN STO: ALZCUR) has appointed co-founder and chief scientific officer Johan Sandin as ...
The Moscow Arbitration Court has rejected claims of the Russian pharmaceutical manufacturer Grotex to provide a compulsory ...
Pfizer’s Elrexfio meets primary endpoint in second Phase III myeloma trial, with higher infections
US pharma giant Pfizer said its Phase III MagnetisMM-32 trial of Elrexfio (elranatamab), a subcutaneous BCMA-CD3 bispecific antibody, met its primary endpoint at a prespecified interim analysis in ...
US biotech Biogen (Nasdaq: BIIB) raised the lower end of its annual earnings guidance after third-quarter revenue rose 11% to ...
Swiss specialty drugmaker Ferring Pharmaceuticals has signed an agreement to acquire US biotechnology company Gameto for up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results